June 24, 2014
by PharmaReviews
0 comments
Bayer has linked up with Dimension Therapeutics to develop a gene therapy for haemophilia A in a deal that could be worth about $250 million to the US biotech. The German group has long been a major player in haemophilia … Continue reading
June 24, 2014
by PharmaReviews
0 comments
Roche has hooked up with healthcare venture capitalist group Versant and research group Inception Sciences to create a new biotechnology company focused on developing treatments for multiple sclerosis. Crowned Inception 5, the newcomer will dedicate itself to designing novel … Continue reading